13 December 2025

CRISPR’s promise is moving from the lab to the clinic. A case that captivated researchers involved an infant known as KJ Muldoon, born with a severe liver mutation and cured with a custom, one‑time CRISPR therapy. This milestone heralds an era where gene editing is tailored to individuals, challenging the pharmaceutical industry’s blockbuster model and raising complex questions about regulation, manufacturing and payment. Personalized therapies reduce rejection risk but upend economies of scale; regulators must evaluate “trials of one”; and insurers must rethink payment models. Entrepreneurs in biotech need to prepare for a world where treatments may be as unique as the patients they serve.

Full Article

The CRISPR revolution began with the ability to make precise cuts in DNA. In its first decade, applications ranged from engineering crops to correcting blood disorders in small clinical trials. But in late 2025, news broke about a profoundly personal intervention: a baby identified publicly only as KJ Muldoon received a CRISPR‑based therapy custom designed for his unique genetic mutation. According to the article by insurance firm HDI Global, the therapy was tailored to his liver cells, correcting the defective sequence that would have otherwise caused a fatal metabolic disorder. This success hints at a future where gene editing is not mass‑produced but bespoke.

Stanford bioengineering professor Stanley Qi contextualizes this shift, noting that CRISPR is evolving from a mere tool into “a discipline, a driving force, and a promise” across science, engineering and medicine. As CRISPR moves into mainstream therapeutics, its personalized nature forces a reconsideration of the pharmaceutical business model. For decades, drug development followed a “blockbuster” approach: invest billions to develop a pill that treats millions. Personalized CRISPR therapies flip this on its head. Doctors extract a patient’s own cells, edit them ex vivo to correct a mutation, then re‑infuse them. The market for each therapy may be one person.

This economic inversion raises many questions. Traditional drugs amortize high research and development costs over large populations. A bespoke therapy priced at several million dollars must justify its value differently. Payment models may involve outcome‑based contracts, where insurers pay over time and cease payments if the therapy stops working. Another option is pooling expenses across rare diseases to spread risk. Entrepreneurs working on gene therapies must collaborate with payers to create sustainable reimbursement structures.

Regulation is another hurdle. Randomized controlled trials (RCTs) are the gold standard for demonstrating drug safety and efficacy, but they rely on large cohorts. Personalized therapies designed for one patient cannot go through a conventional RCT. Regulators like the U.S. Food and Drug Administration will need new frameworks that emphasize biomarkers and individual physiological responses. Manufacturing also becomes more complex: each batch is a single dose, and maintaining a sterile “vein‑to‑vein” chain of custody is critical. Automated, modular clean‑room systems may be required to ensure quality at scale.

For biotech startups, personalized CRISPR therapies open both opportunities and challenges. On the opportunity side, the ability to address ultra‑rare diseases means companies can tackle previously untreatable conditions. First‑mover advantage will be significant: being the sole provider of a cure for a rare genetic disorder can command premium pricing. But on the challenge side, production must be flexible and decentralized. Startups will need to invest in manufacturing platforms that can quickly adapt to different genetic targets without cross‑contamination.

The shift also demands new risk management tools. Because personalized therapies treat small populations, adverse events cannot be diluted across thousands of patients. Insurers and investors will demand robust preclinical data and quality assurance protocols to mitigate liability. Partnerships with specialized insurers may become common, as suggested by HDI’s analysis.

In the long term, personalized gene editing could transform medicine into a service rather than a product. Firms may offer gene‑therapy “subscriptions” where patients receive continuous monitoring, periodic edits and lifetime support. This model aligns incentives: companies earn revenue by keeping patients healthy. However, it further complicates regulatory oversight and requires new financial instruments to manage lifetime risk.

The successful treatment of KJ Muldoon with a personalized CRISPR therapy marks a turning point for precision medicine. The paradigm shift from blockbuster drugs to bespoke cures will disrupt business models, regulation and supply chains. Entrepreneurs who embrace this complexity and innovate around manufacturing, payment and risk will help usher in an era where “one patient, one treatment” is the norm.

Subscribe to our newsletter to stay up to date with the latest breakthroughs in AI, Business, Technology, and Mindset.